NASDAQ : NERV
Minerva Neurosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.05 USD (Oct 30, 2026, 3:16 PM EDT) · Market cap 97.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 110.77M |
| Enterprise Value | 95.51M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 47.75M |
| Shares Outstanding | 47.75M |
| Shares Change (YoY) | +260.56% |
| Shares Change (QoQ) | +80.19% |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 68.78% |
| Float | 34.30M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 20.14 |
| Quick Ratio | 19.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -28.42% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -31.32% |
| Weighted Average Cost of Capital (WACC) | 2.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$56.34M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.01 |
| 52-Week Price Change | -45.15% |
| 50-Day Moving Average | 3.49 |
| 200-Day Moving Average | 4.90 |
| Relative Strength Index (RSI) | 32.45 |
| Average Volume (20 Days) | 167,152 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.41M |
| Short Previous Month | 2.44M |
| Short % of Shares Out | 5.04% |
| Short % of Float | 7.02% |
| Short Ratio (days to cover) | 14.43 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.54M |
| Pretax Income | -394.35M |
| Net Income | -394.35M |
| EBITDA | -28.53M |
| EBIT | -28.54M |
| Earnings Per Share (EPS) | -$14.44 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 75.27M |
| Total Debt | 60.00M |
| Net Cash | 15.27M |
| Net Cash Per Share | $0.32 |
| Equity (Book Value) | -201.56M |
| Book Value Per Share | -4.52 |
| Working Capital | 75.77M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -26.17M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5,442 |
| Net Borrowing | n/a |
| Free Cash Flow | -26.17M |
| FCF Per Share | -$0.55 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -260.56% |
| Shareholder Yield | n/a |
| Earnings Yield | -622.46% |
| FCF Yield | -23.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.33 |
| Price Target Difference | 345.26% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 21, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |